



## Curriculum vitae

Name: **Dominik Heim**  
Titel: PD Dr. med.  
Institution: Hämatologie, Universitätsspital Basel  
Adresse: Petersgraben 4, 4031 Basel, Schweiz  
Tel.: +41 61/328 6311, Fax: +41 61/265 4450  
E-mail: dominik.heim@usb.ch

### Berufserfahrung:

04/2009- Leitender Arzt und Chefarzt-Stv, Hämatologie, Universitätsspital Basel (Prof. A. Gratwohl, Prof. J.Passweg)  
04/2002-03/2009 Oberarzt, Hämatologie, Universitätsspital Basel (Prof. A. Gratwohl)  
04/2000-03/2002 Assistenzarzt, Hämatologie, Universitätsspital Basel (Prof. A. Gratwohl)  
10/1997-03/2000 Postdoctoral Fellow, Hematology Branch, NHLBI, NIH, Bethesda, USA (Dr C. Dunbar)  
02/1996-09/1997 Assistenzarzt Innere Medizin, Department Innere Medizin, Kantonsspital Bruderholz, BL (Prof. H. Kummer)  
03/1993-01/1996 Assistenzarzt Innere Medizin, Department Innere Medizin, Universitätsspital Basel (Proff. W. Stauffacher, K. Gyr)  
11/1990-03/1993 Postdoctoral Fellow, Laboratoire centrale d'hématologie, CHUV, Lausanne (Prof. F. Bachmann)

### Qualifikationen:

2009 Habilitation, Universität Basel  
2003 Facharzttitel Hämatologie FMH  
1997 Facharzttitel Innere Medizin FMH  
04/1990-10/1990 Postgraduate Course in Experimenteller Medizin und Biologie, Universität Zürich (Prof. Zapf)

01/1990                      Promotion, Universität Basel  
12/1989                      Arzt-Diplom, Universität Basel  
07/1989                      ECFMG Diploma

**Forschungserfahrung:**

2010 -                      Mitglied der Studienleitgruppe der CML-IV und CML-V  
                                 Studien der Deutschen CML Studiengruppe  
2007 -                      Study chair der CML-IV Studie (SAKK) für die Schweiz  
2005 -                      Aktives Mitglied der Chronic Leukemia Working Party der  
                                 EBMT (European Group for Blood and Marrow  
                                 Transplantation)  
2003 -                      Aktives Mitglied der Leukemia Project Group der SAKK  
                                 (Schweizerische Arbeitsgruppe für klinische Krebsforschung)  
2000 -                      Principal Investigator in mehr als 50 prospektiven klinischen  
                                 Phase I, II or III Studien (seit 2005 Leitung der klinischen  
                                 Forschung der Hämatologie am Universitätsspital Basel)

**Mitgliedschaften:**

Regionale Stiftung für Krebsforschung SAKK Basel (*Stiftungsrat, Kassier*)  
Schweizerische Gesellschaft für Hämatologie (SGH)  
Schweizerische Arbeitsgruppe für Klinische Krebsforschung (SAKK)  
Deutsche CML Studiengruppe (SHG)  
European Leukemia Net (ELN)  
European Group for Blood and Marrow Transplantation (EBMT)  
European Hematology Association (EHA)  
American Society of Hematology (ASH)  
Center for International Blood and Marrow Transplantation Research (CIBMTR)

## **Publikationen:**

### Original articles:

1. Tschan-Plessl A, Halter JP, Heim D, Medinger M, Passweg JR, Gerull S.: Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation. *Ann Hematol.* 2015 Aug 2. [Epub ahead of print]
2. Binkert L, Medinger M, Halter JP, Heim D, Gerull S, Holbro A, Lengerke C, Weisser M, Passweg JR.: Lower dose anti-thymocyte globulin for GvHD prophylaxis results in improved survival after allogeneic stem cell transplantation. *Bone Marrow Transplant.* 2015 Jun 29. doi: 10.1038/bmt.2015.148. [Epub ahead of print]
3. Passweg JR, Schanz U, Chalandon Y, Güngör T, Baldomero H, Heim D, Nair G, Medinger M, Masouridi-Levrat S, de Faveri GN, Tiercy JM.: High-resolution HLA matching in unrelated donor transplantation in Switzerland: differential impact of class I and class II mismatches may reflect selection of nonimmunogenic or weakly immunogenic DRB1/DQB1 disparities. *Bone Marrow Transplant.* 2015 Jun 8. doi: 10.1038/bmt.2015.129. [Epub ahead of print]
4. Saußele S, Krauß MP, Hehlmann R, Lauseker M, Proetel U, Kalmanti L, Hanfstein B, Fabarius A, Kraemer D, Berdel WE, Bentz M, Staib P, de Wit M, Wernli M, Zettl F, Hebart HF, Hahn M, Heymanns J, Schmidt-Wolf I, Schmitz N, Eckart MJ, Gassmann W, Bartholomäus A, Pezzutto A, Leibundgut EO, Heim D, Krause SW, Burchert A, Hofmann WK, Hasford J, Hochhaus A, Pfirrmann M, Müller MC; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung and the German CML Study Group.: Impact of comorbidities on overall survival in patients with chronic myeloid leukemia: results of the randomized CML Study IV. *Blood.* 2015 Jul 2;126(1):42-9. doi: 10.1182/blood-2015-01-617993. Epub 2015 Apr 27.
5. Eggimann L, Girsberger S, Halter J, Gerull S, Tichelli A, Baldomero H, Heim D, Passweg J, Rovó A.: Kinetics of peripheral blood chimerism for surveillance of patients with leukemia and chronic myeloid malignancies after reduced-intensity conditioning allogeneic hematopoietic SCT. *Bone Marrow Transplant.* 2015 May;50(5):743-5. doi: 10.1038/bmt.2015.3. Epub 2015 Mar 2. No abstract available.
6. Medinger M, Halter J, Heim D, Buser A, Gerull S, Stern M, Passweg J.: Angiogenic markers in plasma cell myeloma patients treated with novel agents. *Anticancer Res.* 2015 Feb;35(2):1085-90.
7. Zeiner E, Blaser LS, Tisljar K, Heim D, Taegtmeyer A. [Fatal agranulocytosis after metamizole reexposure]. *Praxis (Bern 1994).* 2015 Jan 28;104(3):151-4. doi: 10.1024/1661-8157/a001916. German.
8. Vuichard D, Weisser M, Orasch C, Frei R, Heim D, Passweg JR, Widmer AF. Weekly use of fluconazole as prophylaxis in haematological patients at risk for invasive candidiasis. *BMC Infect Dis.* 2014 Nov 11;14:573. doi: 10.1186/s12879-014-0573-5.
9. Gotta V, Widmer N, Decosterd LA, Chalandon Y, Heim D, Gregor M, Benz R, Leoncini-Francini L, Baerlocher GM, Duchosal MA, Csajka C, Buclin T. Clinical usefulness of therapeutic concentration monitoring for imatinib dosage individualization: results from a randomized controlled trial. *Cancer Chemother Pharmacol.* 2014 Dec;74(6):1307-19. doi: 10.1007/s00280-014-2599-1. Epub 2014 Oct 9.

10. Benboubker L, Dimopoulos MA, Dispenzieri A, Catalano J, Belch AR, Cavo M, Pinto A, Weisel K, Ludwig H, Bahlis N, Banos A, Tiab M, Delforge M, Cavenagh J, Geraldes C, Lee JJ, Chen C, Oriol A, de la Rubia J, Qiu L, White DJ, Binder D, Anderson K, Fermand JP, Moreau P, Attal M, Knight R, Chen G, Van Oostendorp J, Jacques C, Ervin-Haynes A, Avet-Loiseau H, Hulin C, Facon T; FIRST Trial Team. Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. *N Engl J Med*. 2014 Sep 4;371(10):906-17. doi: 10.1056/NEJMoa1402551.
11. Gerull S, Medinger M, Heim D, Passweg J, Stern M.: Evaluation of the pretransplantation workup before allogeneic transplantation. *Biol Blood Marrow Transplant*. 2014 Nov;20(11):1852-6. doi: 10.1016/j.bbmt.2014.06.029. Epub 2014 Jun 27.
12. Proetel U, Pletsch N, Lauseker M, Müller MC, Hanfstein B, Krause SW, Kalmanti L, Schreiber A, Heim D, Baerlocher GM, Hofmann WK, Lange E, Einsele H, Wernli M, Kremers S, Schlag R, Müller L, Hänel M, Link H, Hertenstein B, Pfirrmann M, Hochhaus A, Hasford J, Hehlmann R, Sauße S; German Chronic Myeloid Leukemia Study Group; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK).: Older patients with chronic myeloid leukemia ( $\geq 65$  years) profit more from higher imatinib doses than younger patients: a subanalysis of the randomized CML-Study IV. *Ann Hematol*. 2014 Jul;93(7):1167-76.
13. Rueff J, Medinger M, Heim D, Passweg J, Stern M.: Lymphocyte subset recovery and outcome after autologous hematopoietic stem cell transplantation for plasma cell myeloma. *Biol Blood Marrow Transplant*. 2014 Jun;20(6):896-9. doi: 10.1016/j.bbmt.2014.03.007. Epub 2014 Mar 13.
14. Hehlmann R, Müller MC, Lauseker M, Hanfstein B, Fabarius A, Schreiber A, Proetel U, Pletsch N, Pfirrmann M, Haferlach C, Schnittger S, Einsele H, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Ehninger G, Heim D, Heimpel H, Nerl C, Krause SW, Hossfeld DK, Kolb HJ, Hasford J, Sauße S, Hochhaus A.: Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. *J Clin Oncol*. 2014 Feb 10;32(5):415-23. doi: 10.1200/JCO.2013.49.9020. Epub 2013 Dec 2.
15. Kalmanti L, Saussele S, Lauseker M, Proetel U, Müller MC, Hanfstein B, Schreiber A, Fabarius A, Pfirrmann M, Schnittger S, Dengler J, Falge C, Kanz L, Neubauer A, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Krause SW, Heim D, Nerl C, Hossfeld DK, Kolb HJ, Hochhaus A, Hasford J, Hehlmann R; German Chronic Myeloid Leukemia Study Group; Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK).: Younger patients with chronic myeloid leukemia do well in spite of poor prognostic indicators: results from the randomized CML study IV. *Ann Hematol*. 2014 Jan;93(1):71-80. doi: 10.1007/s00277-013-1937-4. Epub 2013 Oct 27.
16. Graux C, Sonet A, Maertens J, Duyster J, Greiner J, Chalandon Y, Martinelli G, Hess D, Heim D, Giles FJ, Kelly KR, Gianella-Borradori A, Longerey B, Asatiani E, Rejeb N, Ottmann OG.: A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies. *Leuk Res*. 2013 Sep;37(9):1100-6. doi: 10.1016/j.leukres.2013.04.025. Epub 2013 Jun 5. Holbro A, Lehmann T, Girsberger S, Stern M, Gambazzi F, Lardinois D, Heim D, Passweg JR, Tichelli A, Bubendorf L, Savic S, Hostettler K, Grendelmeier P, Halter JP, Tamm M. Lung histology predicts outcome of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. *Biol Blood Marrow Transplant*. 2013 Jun;19(6):973-80. doi: 10.1016/j.bbmt.2013.03.017. Epub 2013 Apr 2.

17. Passweg JR, Pabst T, Blum S, Bargetzi M, Li Q, Heim D, Stussi G, Gregor M, Leoncini L, Meyer-Monard S, Brauchli P, Chalandon Y; for the Swiss Group for Clinical Cancer Research (SAKK). Azacytidine for acute myeloid leukemia in elderly or frail patients: a phase II trial (SAKK 30/07). *Leuk Lymphoma*. 2013 May 2. [Epub ahead of print]
18. O'Meara A, Halter J, Heim D, Gerull S, Bucher C, Passweg J, Buser A, Stern M. Allogeneic stem cell transplantation for relapsed or refractory lymphoma after conditioning with BEAM/fludarabine/TBI. *Biol Blood Marrow Transplant*. 2013 Jan;19(1):82-6. doi: 10.1016/j.bbmt.2012.08.008. Epub 2012 Aug 13.
19. Nann-Rütti S, Tzankov A, Cantoni N, Halter J, Heim D, Tsakiris D, Arber C, Buser A, Gratwohl A, Tichelli A, Rovó A. Large granular lymphocyte expansion after allogeneic hematopoietic stem cell transplant is associated with a cytomegalovirus reactivation and shows an indolent outcome. *Biol Blood Marrow Transplant*. 2012 Nov;18(11):1765-70. doi: 10.1016/j.bbmt.2012.07.007. Epub 2012 Jul 14.
20. Finke J, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR, Volin L, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Bertz H, Grishina O, Socié G; ATG-Fresenius Trial Group. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial. *Biol Blood Marrow Transplant*. 2012 Nov;18(11):1716-26. doi: 10.1016/j.bbmt.2012.06.001. Epub 2012 Jun 17.
21. Wannesson L, Bargetzi M, Cairoli A, Cerutti A, Heim D, Hess U, Lerch E, Pabst T, Renner C, Samaras P, Zucca E. Autotransplant for Hodgkin lymphoma after failure of upfront BEACOPP escalated (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone). *Leuk Lymphoma*. 2013 Jan;54(1):36-40. doi: 10.3109/10428194.2012.702903. Epub 2012 Jul 9.
22. Dubois V, Sloan-Béna F, Cesbron A, Hepkema BG, Gagne K, Gimelli S, Heim D, Tichelli A, Delaunay J, Drouet M, Jendly S, Villard J, Tiercy JM.: Pretransplant HLA mistyping in diagnostic samples of acute myeloid leukemia patients due to acquired uniparental disomy. *Leukemia*. 2012 Sep;26(9):2079-85. doi: 10.1038/leu.2012.68. Epub 2012 Mar 14.
23. Nebiker CA, Lardinois D, Junker L, Gambazzi F, Matt P, Habicht JM, Halter J, Heim D, Stern M, Buser AS, Passweg J, Stolz D, Flückiger UM, Weisser M, Battegay M, Bubendorf L, Gratwohl A, Tamm M. Lung resection in hematologic patients with pulmonary invasive fungal disease. *Chest*. 2012 Oct;142(4):988-95.
24. Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Vekemans MC, Biemond B, Sonneveld P, Passweg J, Verdonck L, Legdeur MC, Theobald M, Jacky E, Bargetzi M, Maertens J, Ossenkoppele GJ, Löwenberg B; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); German AML Study Group (AMLSG); Swiss Collaborative Group for Clinical Cancer Research (SAKK).: Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine. *Blood*. 2012 Jun 7;119(23):5367-73. doi: 10.1182/blood-2011-11-389841. Epub 2012 Mar 15.
25. Sigle JP, Medinger M, Stern M, Infanti L, Heim D, Halter J, Gratwohl A, Buser A. Prospective change control analysis of transfer of platelet concentrate production from a specialized stem cell transplantation unit to a blood transfusion center. *J Clin Apher*. 2012;27(4):178-82. doi: 10.1002/jca.21214. Epub 2012 Mar 10.

26. Bettens F, Passweg J, Schanz U, Chalandon Y, Heim D, Güngör T, Stussi G, Nicoloso G, Baldomero H, Gratwohl A, Tiercy JM. Impact of HLA-DPB1 Haplotypes on Outcome of 10/10 Matched Unrelated Hematopoietic Stem Cell Donor Transplants Depends on MHC-Linked Microsatellite Polymorphisms. *Biol Blood Marrow Transplant*. 2012 Apr; 18: 608-616
27. Medinger M, Buser A, Stern M, Heim D, Halter J, Rovo A, Tzankov A, Tichelli A, Passweg J. Aplastic anemia in association with a lymphoproliferative neoplasm: Coincidence or causality? *Leuk Res*. 2012 Feb;36(2):250-1. doi: 10.1016/j.leukres.2011.09.008. Epub 2011 Oct 1.
28. Schneider T, Halter J, Heim D, Passweg J, Stern M, Tichelli A, Weisser M, Gerull S. Pre-emptive diagnosis and treatment of fungal infections-evaluation of a single-centre policy. *Clin Microbiol Infect*. 2012 Feb;18(2):189-94
29. Socié G, Schmoor C, Bethge WA, Ottinger HD, Stelljes M, Zander AR, Volin L, Ruutu T, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Kolb HJ, Bertz H, Egger M, Grishina O, Finke J; for the ATG-Fresenius Trial Group. Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius. *Blood*. 2011 Jun 9;117(23):6375-6382.
30. Löwenberg B, Pabst T, Vellenga E, van Putten W, Schouten HC, Graux C, Ferrant A, Sonneveld P, Biemond BJ, Gratwohl A, de Greef GE, Verdonck LF, Schaafsma MR, Gregor M, Theobald M, Schanz U, Maertens J, Ossenkoppele GJ; Dutch-Belgian Cooperative Trial Group for Hemato-Oncology (HOVON) and Swiss Group for Clinical Cancer Research (SAKK) Collaborative Group. Cytarabine dose for acute myeloid leukemia. *N Engl J Med*. 2011 Mar 17;364(11):1027-36. doi: 10.1056/NEJMoa1010222.
31. Rovo A, Daikeler T, Halter J, Heim D, Tsakiris DA, Stern M, Waltimo T, Studt JD, Tyndall A, Gratwohl A, Tichelli A. Late altered organ function in very long term survivors after allogeneic hematopoietic stem cell transplantation: a paired comparison with their HLA-identical sibling donor. *Haematologica*. 2010 Sep 17. [Epub ahead of print]
32. Gerull S, Arber C, Bucher C, Buser A, Gratwohl A, Halter J, Heim D, Tichelli A, Stern M. Cyclosporine levels and rate of graft rejection following non-myeloablative conditioning for allogeneic hematopoietic SCT. *Bone Marrow Transplant*. 2010 Aug 9. [Epub ahead of print]
33. O'Meara A, Pabst T, Heim D, Gerull S, Bucher C, Halter J, Arber C, Rovò A, Tichelli A, Gratwohl A, Stern M: High-dose melphalan with or without stem cell support before myeloablative allo-SCT for remission induction in patients with advanced relapsed or refractory AML. *Bone Marrow Transplant*. 2010 Aug 9. [Epub ahead of print]
34. Cantoni N, Gerull S, Heim D, Halter J, Bucher C, Buser A, Tsakiris DA, Passweg J, Tichelli A, Stern M, Gratwohl A. Order of application and liver toxicity in patients given BU and CY containing conditioning regimens for allogeneic hematopoietic SCT. *Bone Marrow Transplant*. 2010 Jun 14. [Epub ahead of print]
35. Cantoni N, Hirsch HH, Khanna N, Gerull S, Buser A, Bucher C, Halter J, Heim D, Tichelli A, Gratwohl A, Stern M. Evidence for a Bidirectional Relationship between Cytomegalovirus Replication and acute Graft-versus-Host Disease. *Biol Blood Marrow Transplant*. 2010 Sep;16(9):1309-1314.
36. Luft D, Schmoor C, Wilson C, Widmer AF, Bertz H, Frei R, Heim D, Dettenkofer M: Central venous catheter-associated bloodstream infection and colonisation of insertion site

and catheter tip. What are the rates and risk factors in haematology patients? *Ann Hematol* 2010; DOI 10.1007/s00277-010-1005-2

37. Brauchli YB, Wais T, Gratwohl A, Heim D, Schipf A, Diebold J, Krähenbühl S. Fatal myocardial infarction during nilotinib treatment in a 60-year-old male patient. *Acta Oncol.* 2010 Mar 23. [Epub ahead of print]
38. Leupin N, Schuller JC, Solenthaler M, Heim D, Rovó A, Beretta K, Gregor M, Bargetzi MJ, Brauchli P, Himmelmann A, Hanselmann S, Zenhäusern R. Efficacy of rituximab and cladribine in patients with chronic lymphocytic leukemia and feasibility of stem cell mobilization: a prospective multicenter phase II trial (protocol SAKK 34/02). *Leuk Lymphoma.* 2010 Mar 10. [Epub ahead of print]
39. Rovó A, Stüssi G, Meyer-Monard S, Favre G, Tsakiris D, Heim D, Halter J, Arber C, Passweg J, Gratwohl A, Tichelli A. Sideroblastic changes of the bone marrow can be predicted by the erythrogram of peripheral blood. *Int J Lab Hematol.* 2009 Aug 25. [Epub ahead of print]
40. Finke J, Bethge WA, Schmoor C, Ottinger HD, Stelljes M, Zander AR, Volin L, Ruutu T, Heim DA, Schwerdtfeger R, Kolbe K, Mayer J, Maertens JA, Linkesch W, Holler E, Koza V, Bornhäuser M, Einsele H, Kolb HJ, Bertz H, Egger M, Grishina O, Socié G; ATG-Fresenius Trial Group. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial. *Lancet Oncol.* 2009 Sep;10(9):855-64.
41. Dettenkofer M, Wilson C, Gratwohl A, Schmoor C, Bertz H, Frei R, Heim D, Luft D, Schulz S, Widmer AF. Skin disinfection with octenidine dihydrochloride for central venous catheter site care: a double-blind, randomized, controlled trial. *Clin Microbiol Infect.* 2009 Aug 17. [Epub ahead of print]
42. Zenhäusern R, Schmitz SF, Solenthaler M, Heim D, Meyer-Monard S, Hess U, Leoncini L, Bargetzi M, Rufener B, Tobler A. Randomized trial of daily versus weekly administration of 2-chlorodeoxyadenosine in patients with hairy cell leukemia: a multicenter phase III trial (SAKK 32/98). *Leuk Lymphoma.* 2009 Aug 4:1-11.
43. Orasch C, Weisser M, Mertz D, Conen A, Heim D, Christen S, Gratwohl A, Battagay M, Widmer A, Flückiger U. Comparison of infectious complications during induction/consolidation chemotherapy versus allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant.* 2009 Aug 10. [Epub ahead of print]
44. Stussi G, Halter J, Tichelli A, Meyer-Monard S, Buser AS, Arber C, Heim D, Passweg JR, Rischewski J, Paulussen M, Gratwohl A.: Double allogeneic hematopoietic SCT as a rescue therapy for poor-risk hematological malignancies. *Bone Marrow Transplant.* 2009 Jun 29. Epub ahead of print
45. Apperley JF, Cortes JE, Kim DW, Roy L, Roboz GJ, Rosti G, Bullorsky EO, Abruzzese E, Hochhaus A, Heim D, de Souza CA, Larson RA, Lipton JH, Khoury HJ, Kim HJ, Sillaber C, Hughes TP, Erben P, Van Tornout J, Stone RM.: Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START A trial. *J Clin Oncol.* 2009 Jul 20;27(21):3472-9.
46. Baerlocher GM, Rovó A, Müller A, Matthey S, Stern M, Halter J, Heim D, Rischewski J, Gratwohl A, Tichelli A.: Cellular senescence of white blood cells in very long-term survivors after allogeneic hematopoietic stem cell transplantation: the role of chronic graft-versus-host disease and female donor sex. *Blood.* 2009 Jul 2;114(1):219-22.
47. Meyer-Monard S, Passweg J, Siegler U, Kalberer C, Koehl U, Rovó A, Halter J, Stern M, Heim D, Alois Gratwohl JR, Tichelli A. :Clinical-grade purification of natural killer cells

in haploidentical hematopoietic stem cell transplantation. *Transfusion*. 2009 Feb;49(2):362-71.

48. Medinger M, Skoda R, Gratwohl A, Theocharides A, Buser A, Heim D, Dirnhofner S, Tichelli A, Tzankov A: Angiogenesis and vascular endothelial growth factor-/receptor expression in myeloproliferative neoplasms: correlation with clinical parameters and JAK2-V617F mutational status. *Br J Haematol*. 2009 Jul;146(2):150-7.
49. Cantoni N, Weisser M, Buser A, Arber C, Stern M, Heim D, Halter J, Christen S, Tsakiris DA, Droll A, Frei R, Widmer AF, Flückiger U, Passweg J, Tichelli A, Gratwohl A. Infection prevention strategies in a stem cell transplant unit: Impact of change of care in isolation practice and routine use of high dose intravenous immunoglobulins on infectious complications and transplant related mortality. *Eur J Haematol*. 2009 Aug;83(2):130-8.
50. Stalder MP, Rovó A, Halter J, Heim D, Silzle T, Passweg J, Rischewski J, Stern M, Arber C, Buser A, Meyer-Monard S, Tichelli A, Gratwohl A. Aplastic anemia and concomitant autoimmune diseases. *Ann Hematol*. 2009 Jul;88(7):659-65.
51. Heim D, Passweg JP, Gregor M, Buser A, Theocharides A, Arber C, Meyer-Monard S, Tichelli A, Gratwohl A. Patient and product factors affecting platelet transfusion results. *Transfusion*. 2008 Apr; 48: 681-87.
52. Rovó A, Daikeler T, Stern M, Halter J, Studt JD, Buser A, Heim D, Rischewski J, Medinger M, Tyndall A, Gratwohl A, Tichelli A. Physical and not mental health is impaired in very long-term survivors after HSCT compared with their respective donors: a paired analysis. *Blood*. 2008 Feb 1;111(3):1740-1.
53. Khanna N, Widmer AF, Decker M, Steffen I, Halter J, Heim D, Weisser M, Gratwohl A, Fluckiger U, Hirsch HH. Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. *Clin Infect Dis*. 2008 Feb 1;46(3):402-12.
54. Tichelli A, Bucher C, Rovo A, Stussi G, Stern M, Paulussen M, Halter J, Meyer-Monard S, Heim D, Tsakiris DA, Biedermann B, Passweg JR, Gratwohl A. Premature cardiovascular disease after allogeneic stem cell transplantation. *Blood*. 2007 Nov 1; 2007;110: 3463-3471
55. Tiercy JM, Nicoloso G, Passweg J, Schanz U, Seger R, Chalandon Y, Heim D, Gungor T, Schneider P, Schwabe R, Gratwohl A. The probability of identifying a 10/10 HLA allele-matched unrelated donor is highly predictable. *Bone Marrow Transplant*. 2007 Sep;40(6):515-22.
56. Arber C, Buser A, Heim D, Weisser M, Tyndall A, Tichelli A, Passweg J, Gratwohl A. Septic polyarthritis with *Ureaplasma urealyticum* in a patient with prolonged agammaglobulinemia and B-cell aplasia after allogeneic HSCT and rituximab pretreatment. *Bone Marrow Transplant*. 2007 Sep;40(6):597-8
57. Bucher C, Stern M, Buser A, Heim D, Paulussen M, Halter J, Tsakiris D, Droll A, Meyer-Monard S, Tichelli A, Passweg J, Gratwohl A. Role of primacy of birth in HLA-identical sibling transplantation. *Blood*. 2007 Jul 1;110(1):468-9.
58. Conen A, Weisser M, Orasch Jorg C, Battegay M, Trampuz A, Frei R, Christen S, Heim D, Gratwohl A, Fluckiger U. *Candida krusei*- a serious complication in patients with hematological malignancies: successful treatment with caspofungin. *Transpl Infect Dis*. 2007 May 19; [Epub ahead of print]



59. Dobr T, Passweg J, Weber C, Tichelli A, Heim D, Meyer J, Gratwohl A, Waltimo T. Oral health risks associated with HLA-types of patients undergoing hematopoietic stem cell transplantation. *Eur J Haematol.* 2007 Jun; 78(6):495-9.
60. Buser AS, Stern M, Bucher C, Arber C, Heim D, Halter J, Meyer-Monard S, Stussi G, Lohri A, Ghielmini M, Tichelli A, Passweg JR, Gratwohl A. High-dose chemotherapy using BEAM without autologous rescue followed by reduced-intensity conditioning allogeneic stem-cell transplantation for refractory or relapsing lymphomas: a comparison of delayed versus immediate transplantation. *Bone Marrow Transplant.* 2007 Mar; 39(6):335-40.
61. Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, Roboz GJ, Amadori S, de Souza CA, Lipton JH, Hochhaus A, Heim D, Larson RA, Branford S, Muller MC, Agarwal P, Gollerkeri A, Talpaz M. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. *Blood* 2007 May 15; 109(10):4143-50.
62. Stern M, Passweg J, Tiercy JM, Genitsch S, Meyer-Monard S, Heim D, Tichelli A, Gratwohl A, Nissen-Druey C: Human Leukocyte Antigen DR15 Is Associated with Reduced Relapse Rate and Improved Survival after Human Leukocyte Antigen-Identical Sibling Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant.* 2006 Nov; 12(11):1169-75.
63. Martino R, Parody R, Fukuda T, Maertens J, Theunissen K, Ho A, Mufti GJ, Kroger N, Zander AR, Heim D, Paluszewska M, Selleslag D, Steinerova K, Ljungman P, Cesaro S, Nihtinen A, Cordonnier C, Vazquez L, Lopez-Duarte M, Lopez J, Cabrera R, Rovira M, Neuburger S, Cornely O, Hunter AE, Marr KA, Dornbusch HJ, Einsele H: Impact of the intensity of the pre-transplant conditioning regimen in patients with prior invasive aspergillosis undergoing allogeneic hematopoietic stem cell transplantation: a retrospective survey of the infectious diseases working party of the european group for blood and marrow transplantation. *Blood.* 2006 Nov 1;108(9):2928-36.
64. Rovo A, Tichelli A, Passweg JR, Heim D, Meyer-Monard S, Holzgreve W, Gratwohl A, De Geyter C. Spermatogenesis in long-term survivors after allogeneic hematopoietic stem cells transplantation is associated with age, time interval since transplantation and apparently with absence of chronic GvHD. *Blood.* 2006 Aug 1;108(3):1100-5.
65. Heim D, Friess D, Christen S, Stüssi G, Meyer-Monard S, Tichelli A, Passweg JP, Gratwohl A: Intensive chemotherapy and autologous hematopoietic stem cell mobilization, collection and transplantation with simultaneous Imatinib therapy in patients with blast crisis chronic myeloid leukaemia. *Leukemia.* 2006 May;20(5):898-900
66. Arber C, Buser A, Heim D, Gratwohl A, Tichelli A, Passweg JR. Cyclosporine-responsive thrombocytopenia in a patient with chloramphenicol-associated myelodysplastic syndrome. *Eur J Haematol.* 2006 Mar;76(3):255-7
67. Martinez MT, Bucher C, Stussi G, Heim D, Buser A, Tsakiris DA, Tichelli A, Gratwohl A, Passweg JR. Transplant-associated microangiopathy (TAM) in recipients of allogeneic hematopoietic stem cell transplants. *Bone Marrow Transplant.* 2005 Dec; 36(11):993-1000.
68. Rovo A, Meyer-Monard S, Heim D, Arber C, Passweg JR, Gratwohl A, Tichelli A. No evidence of plasticity in hair follicles of recipients after allogeneic hematopoietic stem cell transplantation. *Exp Hematol.* 2005 Aug; 33(8):909-11.

69. Seifert B, Passweg JR, Heim D, Rovo A, Meyer-Monard S, Buechner S, Tichelli A, Gratwohl A. Complete remission of alopecia universalis after allogeneic hematopoietic stem cell transplantation. *Blood*. 2005 Jan; 105: 426 - 427.
70. Passweg JR, Tichelli A, Meyer-Monard S, Heim D, Stern M, Kuhne T, Favre G, Gratwohl A. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. *Leukemia*. 2004 Nov; 18(11): 1835-8.
71. Kostova G, Heim D, Passweg J, Buser A, Tichelli A, Gratwohl A. Cytopenia and hematopoietic recovery after low intensity conditioning transplants. *Croat Med J*. 2004 Aug; 45(4):445-50.
72. Buser AS, Heim D, Bucher C, Tichelli A, Gratwohl A, Passweg JR. High-dose chemotherapy using BEAM for tumor debulking without stem cell support followed by early allogeneic reduced intensity conditioning transplantation to induce a graft-versus-lymphoma effect in patients with high risk or refractory lymphoma. *Bone Marrow Transplant*. 2004 May; 33(10):1011-4.
73. Heim D, Ebnöther M, Meyer-Monard S, Tsakiris D, Linn M, Tichelli A, Gratwohl A: G-CSF for Imatinib-induced neutropenia. *Leukemia* 2003 April; 17(4): 805-7
74. Passweg JR, Meyer-Monard S, Gregor M, Favre G, Heim D, Ebnöther M, Tichelli A, Gratwohl A. High stem cell dose will not compensate for T cell depletion in allogeneic non-myeloablative stem cell transplantation. *Bone Marrow Transplant*. 2002 Sep;30(5):267-71
75. Heim D, Hanazono Y, Giri N, Wu T, Childs R, Sellers S, Muul L, Agricola BA, Metzger ME, Donahue RE, Tisdale JF, Dunbar CE. Introduction of a xenogeneic gene via hematopoietic stem cells leads to specific tolerance in a rhesus monkey model. *Molecular Therapy* 2000 June; 1(6): 533-44.
76. Hanazono Y, Brown KE, Handa A, Metzger ME, Heim D, Kurtzman GJ, Donahue RE, Dunbar CE. In vivo marking of rhesus monkey lymphocytes by adeno-associated viral vectors: direct comparison with retroviral vectors. *Blood*. 1999 Oct; 94(7): 2263-70.
77. Lupu F, Heim DA, Bachmann F, Hurni M, Kakkar VV, Kruithof EK. Plasminogen activator expression in human atherosclerotic lesions. *Arterioscler Thromb Vasc Biol*. 1995 Sep;15(9):1444-55.
78. Lupu F, Heim D, Bachmann F, Kruithof EK. Expression of LDL receptor-related protein/alpha 2-macroglobulin receptor in human normal and atherosclerotic arteries. *Arterioscler Thromb*. 1994 Sep;14(9):1438-44.
79. Lupu F, Bergonzelli GE, Heim DA, Cousin E, Genton CY, Bachmann F, Kruithof EK. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. *Arterioscler Thromb*. 1993 Jul;13(7):1090-100.

Review articles:

1. Samaras P, Bargetzi M, Betticher DC, Duchosal MA, Heim D, Hess U, Ketterer N, Lerch E, Matthes T, Mey U, Pabst T, Taverna C, Zander T, Renner C.: Current status and updated recommendations for diagnosis and treatment of plasma cell myeloma in Switzerland. *Swiss Med Wkly.* 2015 Feb 21;145:w14100. doi: 10.4414/smw.2015.14100. eCollection 2015.
2. O'Meara A, Holbro A, Meyer S, Martinez M, Medinger M, Buser A, Halter J, Heim D, Gerull S, Bucher C, Rovó A, Kühne T, Tichelli A, Gratwohl A, Stern M, Passweg JR.: Forty years of haematopoietic stem cell transplantation: a review of the Basel experience. *Swiss Med Wkly.* 2014 Feb 24;144:w13928. doi: 10.4414/smw.2014.13928.
3. Passweg JR, Halter J, Bucher C, Gerull S, Heim D, Rovó A, Buser A, Stern M, Tichelli A. Hematopoietic stem cell transplantation: a review and recommendations for follow-up care for the general practitioner. *Swiss Med Wkly.* 2012 Oct 15;142:w13696. doi: 10.4414/smw.2012.13696.
4. Taverna C, Bargetzi M, Betticher D, Gmür J, Gregor M, Heim D, Hess U, Ketterer N, Lerch E, Matthes T, Mey U, Pabst T, Renner C. Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations. *Swiss Med Wkly.* 2010 Sep 13;140:w13054. doi: 10.4414/smw.2010.13054.
5. Heim D.: Pathogenese, Diagnostik und Behandlung des Multiplen Myeloms. *InFo Onkologie* 2009; 12 (8): 43
6. Gratwohl A, Heim D.: Current role of stem cell transplantation in chronic myeloid leukaemia. *Best Pract Res Clin Haematol.* 2009 Sep;22(3):431-43.
7. Heim D: Einsatz der Tyrosinkinase-Inhibitoren der zweiten Generation bei chronischer myeloischer Leukämie. *Schweiz. Med. Forum* 2009; 9(39):686-689
8. Heim D, Gratwohl A: Role of allogeneic transplantation in chronic myeloid leukaemia. *Expert Review of Hematology* 2008; 1: 41-50.
9. Gratwohl A, Heim D, Bargetzi M, Baerlocher GM, Chalandon Y, Duchosal M, Gregor M, Hess U, Oppliger E, Passweg J, Schanz U, Dirnhofer S: Behandlung der chronischen myeloischen Leukämie 2007. Empfehlungen der Schweizerischen Arbeitsgruppe CML. *Schweiz. Med. Forum* 2007;7:934-940
10. Heim D: Tyrosinkinase-Inhibitoren in der Behandlung der Chronischen Myeloischen Leukämie. *Ther Umsch.* 2006 Apr;63(4):249-54.
11. Bosly A, Muylle L, Noens L, Pietersz R, Heim D, Hübner R, Selleslag D, Toungouz M, Ferrant A, Sondag D: Guidelines for the transfusion of platelets. *Acta Clinica Belgica* 2007; 62 (1): 36-47
12. Heim DA, Dunbar CE: Hematopoietic stem cell gene therapy: towards clinically significant gene transfer efficiency. *Immunological Reviews* 2000, Vol.178; 29-38

Abstracts:

- 1 Heim D: Current role of allogeneic stem cell transplantation in CML. Gemeinsame Jahrestagung DGHO, OeGHO, SGMO, SGH, 2009 Mannheim. V368
- 2 Heim D, Brand R, Olavarria E, Apperley J, Crawley C, Devergie A, Aljurf A, Holowiecki J, Ruutu T, Brinch L, Kolb H.J, de Witte T, Hehlmann R, Gratwohl A: Outcome of chronic myeloid leukaemia patients with allogeneic haematopoietic stem cell transplantation and a low risk score in the imatinib era. A report from the EBMT Chronic Leukemia Working Party and the European Leukemia Net. Bone Marrow Transplant 2008, March; 41 suppl 1, S37, 241.
- 3 Heim D, Passweg JP, Gregor M, Theocharides A, Arber C, Meyer-Monard S, Medinger M, Halter J, Tichelli A, Gratwohl A: Patient and product factors affecting platelet transfusion results. Forum Med Suisse 2007, Mai; Suppl 35, P168
- 4 Heim D, Friess D, Christen S, Stüssi G, Meyer-Monard S, Tichelli A, Passweg JR, Gratwohl A. Intensive combination therapy and autologous PBPC for blast crisis CML revisited. 32<sup>nd</sup> annual Meeting of the EBMT 2006. Bone Marrow Transplant 2006, March; 37 suppl 1, S342
- 5 Heim D, Buser A, Ebnöther M, Meyer-Monard S, Tichelli A, Passweg J, Gratwohl A. Behandlung von Patienten mit fortgeschrittener CML mit Imatinib und allogener hämatopoietischer Stammzelltransplantation. Forum Med Suisse 2003, Mai; Suppl 12, P435
- 6 Heim D, Ebnöther M, Meyer-Monard S, Buser A, Tsakiris D, Favre G, Linn M, Gregor M, Tichelli A, Gratwohl A. G-CSF erlaubt die Weiterführung einer Glivec-Therapie trotz Neutropenie. Forum Med Suisse 2002 April; Suppl 8, P325
- 7 Heim D, Ebnöther M, Meyer-Monard S, Tsakiris D, Trampuz A, Linn M, Passweg J, Gregor M, Favre G, Tichelli A, Gratwohl A: Behandlung der chronisch myeloischen Leukämie: erste Erfahrungen mit Glivec. Forum Med Suisse 2001 April; Suppl 2, P108
- 8 Heim DA, Hanazono Y, Childs R, Metzger M, Donahue RE, Dunbar CE. In vivo persistence of rhesus monkey lymphocytes transduced with a non-expressing retroviral vector compared to rapid clearance of lymphocytes transduced with a neo-expressing vector. Blood 1998 Nov; 92 (Suppl 1), A#2833

80.